FitzmauriceC, AllenC, BarberRM, BarregardLt, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis of the global burden of disease study. JAMA Oncology2017;3: 524–48.
ColemanRE, LiptonA, RoodmanCD. Metastasis and bone loos: advancing treatment and prevention. Cancer Treat Rev2010;36:615–20.
4.
SundermeyerML, MeropolNJ, RogatikoA, Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer2005;5:108–13.
5.
HoCL, ChenS, ChengTK, LeungYL. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology2011;258:515–23.
6.
XiongZ, DengG, HuangX, LiX, Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res2018;10:287–95.
7.
BaekSJ, HurH, MinBS, BaikSH, The characteristics of bone metastases in patients with colorectal cancer: a long-term report from a single institution. World J Surg2016;40:982–6.
8.
PruksakornD, PhanphaisamP, SettakornJ, ArpornchayanonU, Prognostic score for life expectancy evaluation of lung cancer patients after bone metastases. J Bone Oncol2018;10:1–5.
9.
SorensenMS, GerdsTA, HindsoKPrediction of survival after surgery due to skeletal metastases in the extremities. Bone Joint J2016;95:271–7.
10.
PinY, Paix, FevreCL, AntoniD, A systematic review of palliative bone radiotherapy based on pain relief and retreatment rates. Critical Rev Oncolo/Hematol2018;123:132–7.
11.
MokF, LiK, YeungR, WongKH, ‘Who', ‘when’ and ‘how’ in re-irradiation of recurrent painful bone metastases. J Bone Oncol2013;2:33–7.
12.
GrecoC, ParesO, PimentelN, MoserE, Spinal metastases from conventional fractionated radiotherapy to single-dose SBRT. Rep Pract Oncol Radiother2015;20:454–63.
13.
ColemanRE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res2006;12:S6243–9.
14.
DenieleS, SandroB, SalvatoreI, Natural history of non-small cell lung cancer with bone metastases. Sci Rep2015;5:18670.
15.
JensenAO, JacobosenJB, NorgaardM, YongM, Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer2011;11:29.
16.
Wong NMR. Challenges in management of malignant spinal cord compression. J Orthop Trauma Rehabil2014;18:1.
17.
YeungYN, CheungKKLamTC, A study of the predictive value of the modified Tokuhashi score in metastatic spinal tumour causing spinal cord compression in a Southern Chinese population. J Orthop Trauma Rehabil2014;18:15–21.
18.
KwanKYH, LamTC, ChoiHCW, KohHY, Prediction of survival in patients with symptomatic spinal metastases: comparison between the Tokuhashi score and expert oncologist. Surg Oncol2018;27:7–10.
19.
HeinzT, StoikW, VesseiV.Treatment and results of pathological fractures. A collboarte study from 1965 to 1985 of 16 Austrian hospitals. Der Unfallchirurg1989;92:477–85.
20.
MaduakonamDE, YauCHR, HoWYK, Profile of surgically-treated metastatic extremity bone tumours at a university hospital in Hong Kong. J Orthop Trauma Rehabil2018;24:1–8.
21.
RatasvuoriM, WedinR, KellerJ, Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastatic Registry report of 1,195 operated skeletal metastasis. Surg Oncol2013;33:132–8.
22.
KirkinisMN, LyneCJ, WilsonMD, ChoongPFM. Metastatic bone disease: a review of survival, prognostic factors and outcomes following surgical treatment of the appendicular skeleton. Eur J Surg Oncol2016;42:1787–97.
23.
ErraniC, MavrogenisAF, CevolaniL, SpinelliS, Treatment for long bone metastases based on a systematic literature review. Eur J Orthop Surg Tratumatol2017;27:205–511.
24.
SteensmaM, BolandPJ, MorrisCD, AthanasianE, Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res2012;470:920–6.
25.
ArviniusC, ParraJL, MateoLS, MarotoRG. Benefits of early intramedullary nailing in femoral metastases. Int Orthop2014;38:129–32.
26.
MirelsH.Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fracture. Clin Orthop Relat Res1989;249:256–64.
27.
WeberKL, O'ConnorMI. Operative treatment of long bone metastases: focus on the femur. Clin Orthop Relat Res2003;415:S276–8.
28.
HadjiP, AaproMS, BodyJJ, GnantM, Management of aromatase inhibitor-associated bone loss in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG. J Bone Oncol2017;7:1–12.
29.
EdwardsBJ, GradisharWJ, SmithEM, PachecoJA, Elevated incidence of fractures in women with invasive breast cancer. Osteopor Int2016;27: 499–507.
30.
GuiseTA. Bone loss and fracture risk associated with cancer therapy. Oncologist2006;11:1121–31.
31.
AlibhaiSM, Duong-HuaM, CheungAM, Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched-cohort study of 19,079 men. J Urol2010;184:918–23.
32.
O'CarriganB, WongMH, WillsonML, SotcklerMR, Bisophosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews2017;10:CD003474. 10 30.
33.
ColemanR, PowlesT, Adjuvant bisphosphonate treatment in early breast cancer: meta-analysis of individual patient data from randomized trials. Lancet2015;386:1353–61.
34.
GnantM, PfeilerG, DubskyPC, Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blinded, placebo-controlled trial. Lancet2015;386:433–43.
35.
MachereyS, MoselI, JahnF, JordanK, Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews 12LCD0062502017;12:26.
36.
AlibhaiSMH, ZukotynskiK, Walker-Dilks, EmmeneggerU, Bone health and bone targeted therapy for prostate cancer: a programme in evidence-based care — Cancer Care Ontario Cancer Practice Guideline. Clin Oncol2017;29:348–55.
37.
BodyJJ, TerposE, TombalB, HadjiP, Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treatment Rev2016;51:46–53.
38.
TerposE, KleberM, EngelhartdtM, European Myeloma Network guidelines for the management of multiple myeloma-related complications. Heamatologica2015;100:1254–66.
39.
ZhangZ, PuF, ShaoZ.The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. J Bone Oncol2017;9:21–4.
40.
MehshawyA, MattarO, AbdulkarimA, KasemS.Denosumab versus bisphosphates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer2018;26:1029–38.